Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 461Neoplasms 378Carcinoma, Non-Small-Cell Lung 354Prostatic Neoplasms 294Colorectal Neoplasms 257Lung Neoplasms 225Multiple Myeloma 206Neoplasm Metastasis 164Pancreatic Neoplasms 156Leukemia, Myeloid, Acute 153Ovarian Neoplasms 136Squamous Cell Carcinoma of Head and Neck 130Melanoma 116Carcinoma, Renal Cell 103Stomach Neoplasms 102Carcinoma, Hepatocellular 100Recurrence 98Lymphoma 94Precursor Cell Lymphoblastic Leukemia-Lymphoma 92Head and Neck Neoplasms 91Lymphoma, Non-Hodgkin 86Glioblastoma 85Brain Neoplasms 84Hematologic Neoplasms 83Urinary Bladder Neoplasms 82Triple Negative Breast Neoplasms 81Endometrial Neoplasms 80Lymphoma, Large B-Cell, Diffuse 79Leukemia, Lymphocytic, Chronic, B-Cell 77Uterine Cervical Neoplasms 74

Interventions

sparsentan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Proteinuria × 30 days × Clear all
NCT07224776 2026-05-18

Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria

Brigham and Women's Hospital

Phase 1 Not yet recruiting
20 enrolled

Neoplasms, Proteinuria

Data powered by HemOnc (CC BY 4.0) Colophon âš¡